Pharmacoeconomics in COPD: lessons for the future.

Area of Science:

• Health Economics
• Pulmonology
• Public Health

Background:

• Chronic Obstructive Pulmonary Disease (COPD) presents a significant global health and economic burden.
• The high cost of COPD treatments necessitates rigorous economic evaluations to determine their value for money.
• Healthcare providers require evidence to guide decisions on resource allocation for effective COPD management.

Purpose of the Study:

• To introduce the principles of economic evaluation in healthcare.
• To critically appraise existing economic evaluations for COPD treatments.
• To assess the quality and comparability of current COPD economic studies.

Main Methods:

• Review and critical appraisal of fifteen existing economic evaluations for COPD.
• Categorization of studies based on design: clinical trial/observational (10) vs. decision analytic models (5).
• Analysis of variations in study design, interventions, outcome measures, and uncertainty handling.

Main Results:

• Significant heterogeneity was observed in study designs, interventions, and outcome measures across the evaluated studies.
• The variability in methodology makes direct comparison of results difficult and limits their utility for decision-makers.
• Existing studies show considerable differences in quality and approach, hindering consistent interpretation.

Conclusions:

• There is a need to harmonize methodologies in future COPD economic evaluations.
• Adopting a modeling framework, using current treatments as comparators, and employing a common effectiveness measure like the Quality-Adjusted Life Year (QALY) are recommended.
• Standardized approaches will enhance the comparability and decision-making utility of economic evaluations for COPD treatments.